New Drugs of 2012, Part 1

Michael A. Mancano, PharmD
Published Online: Tuesday, February 19, 2013

New Drugs of 2012, Part 1

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University School of Pharmacy
Philadelphia, Pennsylvania

Clinical Consultant, Pennsylvania Hospital
Department of Pharmacy
Philadelphia, Pennsylvania


The following contributors have no relevant financial relationships with commercial interests to disclose.

Michael A. Mancano, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA, and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  1. Discuss the clinical indications of the new drugs approved by the FDA in 2012.
  2. Explain the various mechanisms of action of the drugs discussed within this activity.
  3. Identify the clinically relevant drug interactions and the most common adverse reactions for the drugs reviewed in this activity.
  4. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists
Type of activity: Knowledge
Release date: February 10, 2013
Expiration date: February 10, 2015
Estimated time to complete activity: 2 hours
Fee: This lesson is free online

Click here to view this activity.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues